Share on StockTwits

Isis Pharmaceuticals (NASDAQ:ISIS) COO B Lynne Parshall unloaded 89,510 shares of Isis Pharmaceuticals stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $49.49, for a total value of $4,429,849.90. Following the transaction, the chief operating officer now directly owns 4,022 shares of the company’s stock, valued at approximately $199,049. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Several analysts have recently commented on the stock. Analysts at Deutsche Bank initiated coverage on shares of Isis Pharmaceuticals in a research note to investors on Wednesday, January 22nd. They set a “buy” rating and a $60.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Isis Pharmaceuticals in a research note to investors on Tuesday, January 21st. They now have a $49.00 price target on the stock. Finally, analysts at Piper Jaffray upgraded shares of Isis Pharmaceuticals from an “underweight” rating to a “neutral” rating in a research note to investors on Tuesday, November 26th. They now have a $38.00 price target on the stock, up previously from $25.00. One analyst has rated the stock with a sell rating, six have assigned a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $39.50.

Isis Pharmaceuticals (NASDAQ:ISIS) traded up 2.20% during mid-day trading on Friday, hitting $51.06. 1,076,486 shares of the company’s stock traded hands. Isis Pharmaceuticals has a 52-week low of $13.76 and a 52-week high of $51.72. The stock’s 50-day moving average is $43.96 and its 200-day moving average is $34.96. The company’s market cap is $5.927 billion.

Isis Pharmaceuticals (NASDAQ:ISIS) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.21) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.27) by $0.06. The company had revenue of $23.60 million for the quarter, compared to the consensus estimate of $19.82 million. During the same quarter in the prior year, the company posted ($0.37) earnings per share. The company’s quarterly revenue was up 103.4% on a year-over-year basis. On average, analysts predict that Isis Pharmaceuticals will post $-0.53 earnings per share for the current fiscal year.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.